The fall of Cassava Sciences’s Alzheimer’s drug, simufilam

On November 25, Cassava Sciences ended a Phase 3 trial of its controversial Alzheimer’s drug, simufilam, following years of scrutiny.

Illustration: Anna Kim, Photos: Adobe Stock By Caroline Catherman December 11, 2024 • 4 min read TOPICS: Pharma / Clinical Trials & Evidence Generation / Clinical Trials An upcoming Alzheimer’s drug that garnered millions in federal funding has officially been put to bed. Biopharmaceutical company Cassava Sciences announced on November 25 that it had discontinued its Phase 3 clinical trial of drug simufilam. The randomized, double-blind trial found no statistically significant change in patient cognition or function—its co-primary endpoints—after 52 weeks when comparing a 403-person experiment

related reading

• Contrary Research on X: "The Virtual Cell Revolution" / Xx.com
• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
• It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough | Jonathan Schott | The Guardiantheguardian.com
• Nintil - The failure of monoclonal antibody therapy for Alzheimer's Disease, implications for the Amyloid Cascade Hypothesisnintil.com
• Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
• About Us – Hindenburg Researchhindenburgresearch.com
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• “Real world” eligibility for aducanumab: A Podcast with Tim Anderson and Marco Canevelligeripal.org
• Nature's drug database - The Works in Progress Newsletterworksinprogress.news
• The 23andMe Deal - Cremieux Recueilcremieux.xyz
• Why the FDA Is Slow to Remove Drugspress.asimov.com
• There is way too much serendipity — LessWronglesswrong.com